Kevin J. Tracey, MD, president of the Feinstein Institutes for Medical Research, research arm of the 23-hospital Northwell Health, told CNN that he and his team decided to begin the trial after reports from China showed that some coronavirus patients taking the drug had better outcomes than those who did not.
Additionally, a computer model created by Alachua, Fla.-based Alchem Laboratories, which was used to make a list of existing medications that could be used to treat COVID-19 patients, showed famotidine had great promise.
Currently, 187 patients have been enrolled in the trial, but Northwell hopes to enroll 1,200.
The patients will receive doses of famotidine that are nine times greater than what a person would usually take for heartburn.
“You should not go to the drugstore and take a bunch of heartburn medicine,” Dr. Tracey told CNN.
Dr. Tracey said that it is unclear whether the drug will benefit COVID-19 patients, but if it works, it could be brought to scale relatively easily, as “it’s generic, it’s plentiful and it’s inexpensive.”
More articles on pharmacy:
CMS cleared to survey 340B hospitals on their drug acquisition costs
SSM Health to close 2 retail pharmacies
The race to develop a COVID-19 vaccine: 5 updates
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.